Biotech | March 03, 2022
Medix Biochemica announces expansion of its porfolio
The accelerated growth of Medix Biochemica will establish its status as the ultimate IVD raw materials supplier
The accelerated growth of Medix Biochemica will establish its status as the ultimate IVD raw materials supplier
Company expects strong organic growth in sales, EBITDA in 2022
Technology adoption helped the industry to sail through Covid-19 disruption as it understood the need to digitize, learn, and excel
TruPharma has commenced commercial marketing of Sage's approved generic cartridge product
Pankaj Patel, Chairman, Zydus Lifesciences; Umang Vohra, CEO, Cipla; G V Prasad, Co-Chairman, Dr Reddy's; Nilesh Gupta, MD, Lupin and Dilip Shanghvi, MD, Sun Pharmaceuticals sharing their vision to outline the roadmap for the industry.
The NMPA Breakthrough Therapy Designation was based on results from the Phase 2 TRUST trial of ROS1 fusion-positive NSCLC patients treated with taletrectinib, a new generation of potent ROS1 inhibitors
BBL will gain Viatris’ global biosimilars business whose revenues are estimated to be USD 1 billion next year, along with its portfolio of in-licensed biosimilar assets
It is the first approved blood test that can predict likely progression to Alzheimer's Disease up to six years in advance
The method shows the removal of seven types of PFAS – even when all of them are found in the same unit of fluid – at a level of efficiency that approaches 90%, and it does so within a few minutes
Guy Villax was also involved with the EFCG and Rx-360 associations and contributed to legislation being passed on both sides of the Atlantic to fight fake medicines and to level the playing field for GMP manufacturing.
Subscribe To Our Newsletter & Stay Updated
